A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. - Archive ouverte HAL Access content directly
Journal Articles Journal of Allergy and Clinical Immunology Year : 2008

A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.

(1) , (2) , (3) , (4) , (4) , (5) , (4) , (3) , (1) , (1)
1
2
3
4
5

Abstract

BACKGROUND: The spleen tyrosine kinase (Syk) is recognized as a potential pharmaceutical target for the treatment of type I hypersensitivity reactions including allergic rhinitis, urticaria, asthma, and anaphylaxis because of its critical position upstream of immunoreceptor signaling complexes that regulate inflammatory responses in leukocytes. OBJECTIVE: Our aim was to improve the selectivity of anti-Syk therapies by impeding the interaction of Syk with its cellular partners, instead of targeting its catalytic site. METHODS: We have previously studied the inhibitory effects of the anti-Syk intracellular antibody G4G11 on Fc epsilonRI-induced release of allergic mediators. A compound collection was screened by using an antibody displacement assay to identify functional mimics of G4G11 that act as potential inhibitors of the allergic response. The effects of the selected druglike compounds on mast cell activation were evaluated in vitro and in vivo. RESULTS: We discovered compound 13, a small molecule that inhibits Fc epsilonRI-induced mast cell degranulation in vitro and anaphylactic shock in vivo. Importantly, compound 13 was efficient when administered orally to mice. Structural analysis, docking, and site-directed mutagenesis allowed us to identify the binding cavity of this compound, located at the interface between the 2 Src homology 2 domains and the interdomain A of Syk. CONCLUSION: We have isolated a new class of druglike compounds that modulate the interaction of Syk with some of its macromolecular substrates implicated in the degranulation pathway in mast cells.
Fichier principal
Vignette du fichier
Mazuc_Manuscript.pdf (173.02 Ko) Télécharger le fichier
Vignette du fichier
Mazuc_E_Figure_1.ppt (31.5 Ko) Télécharger le fichier
Vignette du fichier
Mazuc_E_Figure_2.ppt (48 Ko) Télécharger le fichier
Vignette du fichier
Mazuc_Figure_1.ppt (2.45 Mo) Télécharger le fichier
Vignette du fichier
Mazuc_Figure_2.ppt (3.24 Mo) Télécharger le fichier
Vignette du fichier
Mazuc_Figure_3.ppt (106.5 Ko) Télécharger le fichier
Vignette du fichier
Mazuc_Figure_4.ppt (2.29 Mo) Télécharger le fichier
Vignette du fichier
Mazuc_Online_Repository.doc (53 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Format : Other
Format : Other
Format : Other
Format : Other
Format : Other
Format : Other
Format : Other

Dates and versions

inserm-00292498 , version 1 (01-07-2008)

Identifiers

Cite

Elsa Mazuc, Bruno O. Villoutreix, Odile Malbec, Thomas Roumier, Sébastien Fleury, et al.. A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.. Journal of Allergy and Clinical Immunology, 2008, 122 (1), pp.188-94, 194.e1-3. ⟨10.1016/j.jaci.2008.04.026⟩. ⟨inserm-00292498⟩
352 View
459 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More